Codexis Inc
CDXS2.450USD
-0.040-1.61%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
221.12MMarket Cap
LossP/E TTM
More Details of Codexis Inc Company
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Company Info
Ticker SymbolCDXS
Company nameCodexis Inc
IPO dateApr 22, 2010
CEODr. Stephen G. Dilly, Ph.D.
Number of employees188
Security typeOrdinary Share
Fiscal year-endApr 22
Address200 Penobscot Dr
CityREDWOOD CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94063
Phone16504218100
Websitehttps://www.codexis.com/
Ticker SymbolCDXS
IPO dateApr 22, 2010
CEODr. Stephen G. Dilly, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. David V. Smith
Mr. David V. Smith
Lead Independent Director
Lead Independent Director
194.28K
+26.74%
Mr. Kevin Norrett
Mr. Kevin Norrett
Chief Operating Officer
Chief Operating Officer
160.27K
+10.73%
Mr. Dennis P. Wolf
Mr. Dennis P. Wolf
Independent Director
Independent Director
147.90K
+38.33%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
132.05K
+45.00%
Dr. Esther Martinborough, Ph.D.
Dr. Esther Martinborough, Ph.D.
Independent Director
Independent Director
129.04K
+46.54%
Ms. Cynthia Collins
Ms. Cynthia Collins
Independent Director
Independent Director
112.16K
+57.58%
Dr. Alison Moore, Ph.D.
Dr. Alison Moore, Ph.D.
Executive Vice President, Chief Technical Officer
Executive Vice President, Chief Technical Officer
98.70K
-43.79%
Dr. Raymond De Vre, Ph.D.
Dr. Raymond De Vre, Ph.D.
Independent Director
Independent Director
88.83K
+85.66%
Mr. Christos Richards
Mr. Christos Richards
Independent Director
Independent Director
85.13K
+92.83%
Ms. Georgia L. Erbez
Ms. Georgia L. Erbez
Chief Financial Officer
Chief Financial Officer
76.88K
+53.75%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David V. Smith
Mr. David V. Smith
Lead Independent Director
Lead Independent Director
194.28K
+26.74%
Mr. Kevin Norrett
Mr. Kevin Norrett
Chief Operating Officer
Chief Operating Officer
160.27K
+10.73%
Mr. Dennis P. Wolf
Mr. Dennis P. Wolf
Independent Director
Independent Director
147.90K
+38.33%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
132.05K
+45.00%
Dr. Esther Martinborough, Ph.D.
Dr. Esther Martinborough, Ph.D.
Independent Director
Independent Director
129.04K
+46.54%
Ms. Cynthia Collins
Ms. Cynthia Collins
Independent Director
Independent Director
112.16K
+57.58%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
EMEA
3.92M
51.96%
America
2.09M
27.68%
APAC
1.54M
20.36%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Opaleye Management Inc.
13.97%
Casdin Capital, LLC
7.98%
BlackRock Institutional Trust Company, N.A.
6.48%
The Vanguard Group, Inc.
5.08%
Fidelity Management & Research Company LLC
4.82%
Other
61.67%
Shareholders
Shareholders
Proportion
Opaleye Management Inc.
13.97%
Casdin Capital, LLC
7.98%
BlackRock Institutional Trust Company, N.A.
6.48%
The Vanguard Group, Inc.
5.08%
Fidelity Management & Research Company LLC
4.82%
Other
61.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.86%
Hedge Fund
28.38%
Investment Advisor/Hedge Fund
19.28%
Individual Investor
2.60%
Research Firm
1.16%
Pension Fund
0.22%
Bank and Trust
0.18%
Venture Capital
0.05%
Insurance Company
0.03%
Other
16.24%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
284
75.27M
90.86%
-6.81M
2025Q1
321
69.35M
83.91%
-9.24M
2024Q4
334
67.97M
82.44%
-9.17M
2024Q3
341
66.67M
93.65%
-3.04M
2024Q2
355
56.24M
79.41%
-16.85M
2024Q1
368
57.66M
81.73%
-20.93M
2023Q4
384
58.98M
84.48%
-18.95M
2023Q3
392
59.46M
85.28%
-19.41M
2023Q2
387
64.66M
96.86%
-12.85M
2023Q1
391
64.45M
97.75%
-12.56M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Opaleye Management Inc.
12.24M
14.78%
+250.00K
+2.08%
Jun 16, 2025
Casdin Capital, LLC
8.10M
9.78%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.23M
7.52%
+27.40K
+0.44%
Mar 31, 2025
The Vanguard Group, Inc.
4.72M
5.7%
+261.14K
+5.85%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.31M
5.2%
+50.27K
+1.18%
Mar 31, 2025
abrdn Inc.
606.29K
0.73%
+97.67K
+19.20%
Mar 31, 2025
Nantahala Capital Management, LLC
2.83M
3.42%
-11.04K
-0.39%
Mar 31, 2025
Telemark Asset Management, LLC
3.00M
3.62%
--
--
Mar 31, 2025
Columbia Threadneedle Investments (US)
2.53M
3.06%
+135.06K
+5.63%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.93M
2.32%
+69.77K
+3.76%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
